Sexually active fertile subjects, and their partners, must agree to use medically accepted double-barrier methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and at least  weeks after termination of study therapy
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s)
Sexually active fertile subjects (male and female) must agree to use medically accepted methods of contraception during the course of the study and for  days after the last dose of study treatment
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used. All subjects of reproductive potential must agree to use both a barrier method and a second method of birth control or practice abstinence during the study and for  months after the last dose of study drug(s)
Sexually active women of childbearing potential enrolled in the study must agree to use two forms of accepted methods of contraception during the course of the study and for  months after their last dose of study drug. Effective birth control includes:
Sexually active fertile subjects, and their partners, must agree to use medically accepted double-barrier methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and at least  months after termination of study therapy
Sexually active patients (men and women) must agree to use medically accepted barrier methods of contraception (e.g. male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used. All sexually active subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s).
Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within  days prior to start of study drug. Sexually active subjects must be willing to use two medically accepted methods of contraception, one of them being a barrier method during the study and for  months (or  months for subjects on Combination Therapy cohort) after last study drug administration.
All sexually active subjects of reproductive potential must agree to use both a medically accepted barrier method (e.g., male or female condom) and a second method of birth control during the course of the study and for  months after the last dose of study drug(s);
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth\r\ncontrol during the course of the study and for  months after the last dose of study drug(s); male subjects must agree to not donate sperm for at least  days after the last dose of carfilzomib
mCRPC EXPANSION COHORT: Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation and for  days after last dose of study drug; sexually active subjects and their female partners must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must also agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s); should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately
Men treated or enrolled on this protocol must also agree to use adequate contraception, prior to the study, for the duration of study participation, and  months after completion; sexually active subjects and their female partners must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must also agree to use both a barrier method and a second method of birth control during the course on the study and for  months after the last dose of study drug(s); should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately
PHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT  ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nMen treated or enrolled on this protocol must also agree to use adequate contraception prior to the study and for the duration of study participation and for  months after last dose of study drug; sexually active subjects and their female partners must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must also agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s); should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately
Sexually active patients (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s)
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s)
Sexually active participants must agree to the use of a medically accepted barrier method of contraception (i.e. male condom or female condom) during the course of the study and for  months following discontinuation of study treatments; for participants of childbearing potential, a barrier method and a second method of contraception must be used
Male and female subjects must agree to medically accepted methods of contraception
Willingness of male and female subjects who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control from the first dose of study drug to  days after the last dose of duvelisib and for  months after last dose of ofatumumab. Sexually active men, and women using oral contraceptive pills, should also use barrier contraception
RENAL & BLADDER: Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s)
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s)
Women of child-bearing potential must agree to use adequate contraception prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she is participating in this study, she should inform her treating physician immediately; sexually active subjects must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s)
Sexually active fertile subjects, and their partners, must agree to use medically accepted double-barrier methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and at least  weeks after termination of study therapy
Sexually active fertile subjects (male and female), and their partners, must agree to use medically accepted methods of contraception (eg, barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for  months after the last dose of study drug(s)
Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for  months after the last dose of study treatment.
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) at the time of the serum pregnancy test (women of childbearing potential only); during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s)
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s)
Sexually active participants and their partners must agree to use medically accepted methods of contraception
Patients of childbearing potential must have a negative pregnancy test prior to the study entry and be practicing an effective form of contraception; sexually active subjects must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug, even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug; pregnant women are excluded from this study
Sexually active fertile subjects, and their partners, must agree to use medically accepted double-barrier methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the study and at least  weeks after termination of study therapy
Willingness of male and female subjects who are not surgically sterile or postmenopausal to use medically acceptable methods of birth control from the first dose of study drug to  days after the last dose of duvelisib and for  months after last dose of ofatumumab. Sexually active men, and women using oral contraceptive pills, should also use barrier contraception
Sexually active fertile patients (male and female), and their partners, must agree to use medically accepted methods of contraception during the course of the study and for  months after the last dose of the study drug
Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and  months after completion of XL (cabozantinib-s-malate) administration; sexually active subjects and their female partners must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must also agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s); should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately
Sexually active fertile subjects, and their partners, must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for  months after the last dose of study drug(s)
Sexually active participants (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all participants of reproductive potential must agree to use both a barrier method and a second method of birth control
Sexually active fertile subjects, and their partners, must agree to use medically accepted methods of contraception (e.g., barrier methods, including male condom, female condom, or diaphragm with spermicidal gel) during the course of the study and for  months after the dose of study drug(s) for Cohorts , , and , and for  months after the surgery for Cohort 
Sexually active subjects must agree to use medically accepted methods of birth control during the course of the study and for  months following discontinuation of study treatments (excluding women who are not of child bearing potential and men who have been sterilized)
Sexually active fertile subjects and their partners must agree to use medically accepted methods of contraception.
Sexually active participants must use medically acceptable methods of contraception during the course of this study
Sexually active subjects and their partners must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  or  weeks for women or men respectively, after the last dose of study drugs, even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  or  weeks for women and men respectively after the last dose of study drugs
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g. male condom, female condom, or diaphragm with spermicidal get) during the course of the study and for  months after the last dose of study drug(s) even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control
Women of child-bearing potential and men must agree to use adequate contraception; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study and for  months after the last dose of study drug(s); sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (eg, male or female condom) during the course of the study and for  months after the last dose of study drug(s), even if oral contraceptives are also used; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control; women of childbearing potential must have a negative pregnancy test at screening
Male subjects who are sexually active must agree to use a condom from the beginning of treatment and for  month after the last dose
Sexually active subject (male and female) must use medically acceptable methods of contraception during the course of the study
Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study; all subjects of reproductive potential must agree to use both a barrier method and a second method of birth control during the course of the study
Sexually active patients and their partners agree to use an accepted method of contraception during the course of the study
